Romosuzumab used to treat a 29-year-old patient with anorexia nervosa related osteoporosis – A case report

IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM

Bone Reports Pub Date : 2024-09-01 DOI:10.1016/j.bonr.2024.101803

{"title":"Romosuzumab used to treat a 29-year-old patient with anorexia nervosa related osteoporosis – A case report","authors":"","doi":"10.1016/j.bonr.2024.101803","DOIUrl":null,"url":null,"abstract":"<div><h3>Summary</h3><p>Osteoporosis and decreased bone density is a frequent complication of anorexia nervosa (AN). As of yet, there have been no studies of accomplished treatment of AN-related osteoporosis with romosuzumab, a monoclonal antibody to sclerostin. We report the first case of a premenopausal, 29-year old patient in Switzerland with decreased bone density and osteoporotic fractures due to anorexia nervosa, who completed the treatment with romosuzumab. There was a significant increase in bone mineral density (BMD) after 12 months of therapy. No serious side effects were reported. To date, only bisphosphonates, denosumab and teriparatide have been evaluated in treatment of AN-related osteoporosis in adolescents and premenopausal individuals respectively. Our report demonstrates that romosuzumab might be an alternative treatment option in patients with anorexia nervosa who are at high risk for osteoporotic fractures. To assess the efficacy and safety of romosuzumab in individuals with AN further studies are needed.</p></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352187224000706/pdfft?md5=787d170bc85bba3b4eb5a7451b1d87ba&pid=1-s2.0-S2352187224000706-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352187224000706","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Summary

Osteoporosis and decreased bone density is a frequent complication of anorexia nervosa (AN). As of yet, there have been no studies of accomplished treatment of AN-related osteoporosis with romosuzumab, a monoclonal antibody to sclerostin. We report the first case of a premenopausal, 29-year old patient in Switzerland with decreased bone density and osteoporotic fractures due to anorexia nervosa, who completed the treatment with romosuzumab. There was a significant increase in bone mineral density (BMD) after 12 months of therapy. No serious side effects were reported. To date, only bisphosphonates, denosumab and teriparatide have been evaluated in treatment of AN-related osteoporosis in adolescents and premenopausal individuals respectively. Our report demonstrates that romosuzumab might be an alternative treatment option in patients with anorexia nervosa who are at high risk for osteoporotic fractures. To assess the efficacy and safety of romosuzumab in individuals with AN further studies are needed.

查看原文本刊更多论文

罗莫单抗用于治疗一名 29 岁神经性厌食症相关骨质疏松症患者--病例报告

摘要骨质疏松症和骨密度下降是神经性厌食症（AN）的常见并发症。迄今为止，还没有关于使用罗莫珠单抗（一种硬骨素单克隆抗体）治疗神经性厌食症相关骨质疏松症的研究。我们报告了瑞士第一例因神经性厌食症导致骨密度下降和骨质疏松性骨折的 29 岁绝经前患者，她完成了罗莫珠单抗的治疗。治疗 12 个月后，患者的骨密度（BMD）明显增加。无严重副作用报告。迄今为止，只有双膦酸盐、地诺单抗和特立帕肽分别被评估用于治疗青少年和绝经前人群的神经性厌食症相关骨质疏松症。我们的报告表明，对于有骨质疏松性骨折高风险的神经性厌食症患者来说，罗莫珠单抗可能是一种替代治疗方案。要评估罗莫珠单抗对神经性厌食症患者的疗效和安全性，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Reports Medicine-Orthopedics and Sports Medicine

CiteScore

4.30

自引率

4.00%

发文量

444

审稿时长

57 days

期刊介绍： Bone Reports is an interdisciplinary forum for the rapid publication of Original Research Articles and Case Reports across basic, translational and clinical aspects of bone and mineral metabolism. The journal publishes papers that are scientifically sound, with the peer review process focused principally on verifying sound methodologies, and correct data analysis and interpretation. We welcome studies either replicating or failing to replicate a previous study, and null findings. We fulfil a critical and current need to enhance research by publishing reproducibility studies and null findings.